Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-TR-24-023

Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

Closed on December 5, 2024.

Posted
April 3, 2024
Close date
December 5, 2024
Activity codes
R21
Institutes taking part
NCATS

The notices it replaced

1 notice since 2023, oldest first, each with its awards since FY2014.

  1. Posted 2023RFA-TR-23-0164 awards
  2. Posted 2024RFA-TR-24-023This notice, closed · 6 awards

Replaced by RFA-TR-25-002.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
10
10 new
Median first-year cost
$423,384
$3,798,962 in all
Institutions
10
10 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. CHILDREN'S HOSP OF PHILADELPHIA1
  2. CLEMSON UNIVERSITY1
  3. DUKE UNIVERSITY1
  4. MYOGENE BIO, LLC1
  5. NORTHWESTERN UNIVERSITY1

and 5 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZTR1 RD-1 (01))10
10 awards under RFA-TR-24-023 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2025RepSox and its analog for prophylactic intervention in RUNX1 haploinsufficiency FPDMM1R21TR005192-01A1Poncz, MortimerCHILDREN'S HOSP OF PHILADELPHIA, PAFirst-year cost $489,500Study section ZTR1
FY2025Development of anti-LTBP4 as a biologic to treat Limb Girdle Muscular Dystrophy 2C1R21TR005472-01Demonbreun, Alexis R.McNally, Elizabeth MNORTHWESTERN UNIVERSITY, ILFirst-year cost $440,000Study section ZTR1
FY2025Src Homology and Collagen (Shc) inhibition for the treatment of transplant-related pulmonary fibrosis.1R21TR005507-01Hsu, Joe LSTANFORD UNIVERSITY, CAFirst-year cost $427,392Study section ZTR1
FY2025Optimization and Preclinical Validation of QTE Therapy for Friedreich's Ataxia1R21TR005475-01Chandran, VijayendranUNIVERSITY OF FLORIDA, FLFirst-year cost $419,375Study section ZTR1
FY2025Optimization of delivery of HEX for treatment of primary amebic encephalitis1R21TR005502-01Chouinard, Christopher DonaldMorris, James CulvinCLEMSON UNIVERSITY, SCFirst-year cost $419,375Study section ZTR1
FY2025Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva1R21TR005159-01A1Jeremic, Jelena GvozdenovicNOSTOPHARMA, LLC, MDFirst-year cost $407,792Study section ZTR1
FY2024Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome1R21TR005157-01 · under RFA-TR-23-016Saba, Julie DUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CAFirst-year cost $463,150Study section ZTR1
FY2024Effective treatment of cystinuria with a novel engineered cyst(e)ine-degrading human enzyme therapy1R21TR005156-01 · under RFA-TR-23-016Georgiou, George GeorgiouUNIVERSITY OF TEXAS AT AUSTIN, TXFirst-year cost $437,761Study section ZTR1
FY2024Triacetin Treatment for Propionic Acidemia by Rebalancing the Acetyl-CoA/Propionyl-CoA Metabolism1R21TR005163-01 · under RFA-TR-23-016Chen, Xiaoxin LukeZhang, GuofangDUKE UNIVERSITY, NCFirst-year cost $184,617Study section ZTR1
FY2024Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy1R21TR005162-01 · under RFA-TR-23-016Young, Courtney SMYOGENE BIO, LLC, CAFirst-year cost $110,000Study section ZTR1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-17-0.3.6. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-TR-24-023: Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) | ConductScience ScienceDex